Skip to main content
SpringerLink
Log in

Vaccines and Immunization

  • Chapter
  • First Online:
Chronic Illness Care

  • 717 Accesses

Abstract

Infectious diseases cause a substantial burden of disease in patients with chronic illness. Although safe and effective vaccines are available to reduce this disease burden, vaccine coverage in patients with chronic illness is often sub-optimal. The classes of vaccines include live attenuated vaccines and inactivated vaccines. Primary care physicians and other care providers should be familiar with national vaccination guidelines for those with chronic diseases and offer appropriate vaccination for this high-risk group. Principles of vaccination in patients with chronic diseases include avoiding live vaccines for patients with most immunocompromising conditions, offering appropriate vaccination to close contacts, and providing vaccines early in the course of illness, when vaccine-elicited immune responses are still robust. Barriers to vaccine uptake include difficulties in access and acceptance; vaccine hesitancy is a difficult problem for medical providers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Plotkin SA, Orenstein WA, Offit PA. Plotkin’s vaccines. 7th ed. Elsevier Inc.; 2017. p. 1–1637.

    Google Scholar 

  2. Jenner E. Dr. Jenner, on the vaccine inoculation. Med Phys J [Internet]. 1800 Jun [cited 2021 Sep 29];3(16):502. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659579/.

  3. Sadanand S. Putting smallpox out to pasture. Nat Res 2021 [Internet]. 2020 Sep 28 [cited 2021 Sep 29]. https://www.nature.com/articles/d42859-020-00007-6.

  4. AAP Committee on Infectious Diseases. Section 1: Active and passive immunization. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, editors. The Red Book. 32nd ed. Itasca, IL: The American Academy of Pediatrics; 2021. p. 1–105.

    Google Scholar 

  5. World Health Organization Team on Immunization V and B. Global vaccine action plan monitoring, evaluation & accountability: Secretariat Annual Report 2020 [Internet]. Geneva; 2020 Jun [cited 2021 Oct 3]. https://www.who.int/publications/i/item/global-vaccine-action-plan-monitoring-evaluation-accountability-secretariat-annual-report-2020.

  6. WHO Immunization Data portal [Internet]. World Health Organization. 2020 [cited 2021 Oct 3]. https://immunizationdata.who.int/.

  7. Wodi AP, Morelli V. Principles of vaccination. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, editors. The Pink Book: epidemiology and prevention of vaccine-preventable diseases. 14th ed. Washington, DC: Centers for Disease Control and Prevention; 2021. p. 1–8.

    Google Scholar 

  8. Siegrist CA. Vaccine immunology. In: Vaccines. 6th ed. W.B. Saunders; 2013. p. 14–32.

    Chapter  Google Scholar 

  9. Bernstein HH, Kilinsky A, Orenstein WA. Immunization practices. In: Kliegman R, editor. Nelson textbook of pediatrics. 21st ed. Philadelphia: Elsevier; 2020. p. 1347–66.

    Google Scholar 

  10. National Center for Immunization and Respiratory Diseases. Immunization Schedules. Published February 17, 2022. https://www.cdc.gov/vaccines/schedules/index.html. Accessed 28 Mar 2022.

  11. WHO recommendations for routine immunization - summary tables [Internet]. World Health Organization. 2021 [cited 2021 Sep 29]. https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/who-recommendations-for-routine-immunization%2D%2D-summary-tables.

  12. Different types of vaccines | History of vaccines [Internet]. The College of Physicians of Philadelphia. 2018 [cited 2021 Sep 29]. https://www.historyofvaccines.org/content/articles/different-types-vaccines.

  13. Klugman KP, Black S, Dagan R, Malley R, Whitney CG. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. In: Vaccines. 6th ed. W.B. Saunders; 2013. p. 504–41.

    Chapter  Google Scholar 

  14. Schiller JT, Lowy DR, Markowitz LE. Human papillomavirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Elsevier; 2013:235–256. doi:https://doi.org/10.1016/B978-1-4557-0090-5.00006-9.

  15. Gomez PL, Robinson JM, Rogalewicz JA. Vaccine manufacturing. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Elsevier; 2013:44–57. doi:https://doi.org/10.1016/B978-1-4557-0090-5.00019-7.

  16. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov [Internet]. 2018 Mar 28 [cited 2021 Sep 29];17(4):261. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906799/.

  17. Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W, et al. COVID-19: coronavirus vaccine development updates. Front Immunol [Internet]. 2020 Dec 23 [cited 2021 Oct 3];11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785583/.

  18. Triggle CR, Bansal D, Ding H, Islam MM, Farag EABA, Hadi HA, et al. A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic. Front Immunol [Internet]. 2021 Feb 26 [cited 2021 Sep 29];12:631139. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952616/.

  19. Grizas AP, Camenga D, Vázquez M. Cocooning. Curr Opin Pediatr. 2012;24:1.

    Article  Google Scholar 

  20. National Center for Immunization and Respiratory Diseases. Appendix A: Glossary of key terms. Interim Guidance on Developing a COVID-19 Case Investigation and Contact Tracing Plan: Overview. Published online January 4, 2022. https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/appendix.html#Key-Terms. Accessed 28 Mar 2022.

  21. Health Information and Quality Authority of Ireland 2021. Protective measures for groups vulnerable to COVID-19 [Internet]. Dublin; 2021 Aug [cited 2021 Oct 3]. https://www.hiqa.ie/reports-and-publications/health-technology-assessment/protective-measures-groups-vulnerable-covid.

  22. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I, Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–18.

    Article  PubMed  Google Scholar 

  23. Crawford NW, Bines JE, Royle J, Buttery JP. Optimizing immunization in pediatric special risk groups. Expert Rev Vaccines. 2011;10(2):175–86.

    Article  PubMed  Google Scholar 

  24. Immunization of persons with chronic diseases: Canadian Immunization Guide - Canada.ca [Internet]. Government of Canada. 2021 [cited 2021 Sep 16]. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-7-immunization-persons-with-chronic-diseases.html.

  25. Doherty M, Schmidt-Ott R, Santos JI, Stanberry LR, Hofstetter AM, Rosenthal SL, et al. Vaccination of special populations: protecting the vulnerable. Vaccine. 2016;34(52):6681–90.

    Article  PubMed  Google Scholar 

  26. Fernandes EG, Rodrigues CCM, Sartori AMC, de Soárez PC, Novaes HMD. Economic evaluation of adolescents and adults’ pertussis vaccination: a systematic review of current strategies. Hum Vaccin Immunother. 2019;15(1):14–27.

    Article  PubMed  Google Scholar 

  27. Vaccination for people who are immunocompromised | The Australian Immunisation Handbook [Internet]. Australian Department of Health. 2020 [cited 2021 Sep 16]. https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-people-who-are-immunocompromised.

  28. Immunization of immunocompromised persons: Canadian Immunization Guide - Canada.ca. Government of Canada. Published December 24, 2020. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-8-immunization-immunocompromised-persons.html#shr-pg0. Accessed 16 Sept 2021.

  29. Yue X, Black CL, Williams WW, Lu P-J, Srivastav A, Amaya A, et al. Influenza vaccination among adults living with persons at high-risk for complications from influenza during early 2016–17 influenza season. Vaccine. 2018;36(52):7987–92.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Gkentzi D, Aggelopoulos K, Karatza A, Sinopidis X, Dimitriou G, Fouzas S. Influenza vaccination among caregivers and household contacts of children with asthma. Vaccine. 2021;39(17):2331–4.

    Article  PubMed  Google Scholar 

  31. National Center for Immunization and Respiratory Diseases. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States [Internet]. Centers for Disease Control and Prevention. 2021 [cited 2021 Nov 21]. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.

  32. Ramsay M, editor. COVID-19—SARS-CoV-2. In: Immunisation against infections disease: The Green Book [Internet]. London: Public Health England; 2021 [cited 2021 Nov 21]. p. 1–40. https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a.

  33. Esposito S, Bruno C, Berardinelli A, Filosto M, Mongini T, Morandi L, et al. Vaccination recommendations for patients with neuromuscular disease. Vaccine. 2014;32(45):5893–900.

    Article  PubMed  Google Scholar 

  34. Miller E, Wodi P. General best practice guidance for immunization. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, editors. The Pink Book: epidemiology and the prevention of vaccine-preventable diseases. Centers for Disease Control and Prevention; 2021. p. 9–28.

    Google Scholar 

  35. Kroger AT, Atkinson WL, Pickering LK. General immunization practices. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Elsevier; 2013. p. 88–112. https://doi.org/10.1016/B978-1-4557-0090-5.00002-1.

    Chapter  Google Scholar 

  36. Cortina G, Ojinaga V, Zlamy M, Giner T, Riedl M, Rauchenzauner M, et al. Vaccination status in pediatric solid-organ transplant recipients and their household members. Exp Clin Transplant. 2019;17(4):429–34.

    Article  PubMed  Google Scholar 

  37. Rensink MJ, van Laarhoven HWM, Holleman F. Cocoon vaccination for influenza in patients with a solid tumor: a retrospective study. Support Care Cancer. 2021;29(7):3657–66.

    Article  CAS  PubMed  Google Scholar 

  38. Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clin Infect Dis. 2011;52(7):911–6.

    Article  PubMed  Google Scholar 

  39. Smith CE. Prospects for the control of infectious disease. Proc R Soc Med. 1970;63(11 Part 2):1181–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Anderson EJ, Daugherty MA, Pickering LK, Orenstein WA, Yogev R. Protecting the community through child vaccination. Clin Infect Dis. 2018;67(3):464–71.

    Article  PubMed  Google Scholar 

  41. Halloran ME. Overview of vaccine field studies: types of effects and designs. J Biopharm Stat. 2006;16(4):415–27.

    Article  CAS  PubMed  Google Scholar 

  42. Delamater PL, Street EJ, Leslie TF, Yang YT, Jacobsen KH. Complexity of the basic reproduction number (R 0). Emerg Infect Dis. 2019;25(1):1–4.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295(14):1668–74.

    Article  CAS  PubMed  Google Scholar 

  44. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Hanquet G, Krizova P, Valentiner-Branth P, Ladhani SN, Nuorti JP, Lepoutre A, et al. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax. 2019;74(5):473–82.

    Article  PubMed  Google Scholar 

  46. Kim TH, Johnstone J, Loeb M. Vaccine herd effect. Scand J Infect Dis. 2011;43(9):683–9.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Patel M, Lee AD, Redd SB, Clemmons NS, McNall RJ, Cohn AC, et al. Increase in measles cases—United States, January 1–April 26, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(17):402–4.

    Article  PubMed  Google Scholar 

  48. Bernadou A, Astrugue C, Méchain M, le Galliard V, Verdun-Esquer C, Dupuy F, et al. Measles outbreak linked to insufficient vaccination coverage in Nouvelle-Aquitaine Region, France, October 2017 to July 2018. Eur Secur. 2018;23(30):1800373.

    Google Scholar 

  49. Raybern C, Fornshell S, DeWeese L. Community-wide outbreak of pertussis in a highly unvaccinated community—Pottawatomie County, June 2014 [Internet]. Westmoreland, KS; 2016 Aug [cited 2021 Aug 6]. https://www.kdheks.gov/epi/download/Pott_County_Pertussis_Outbreak_Report_final.pdf.

  50. Caron C. Chickenpox outbreak at school linked to vaccine exemptions - The New York Times [Internet]. New York Times. 2018 [cited 2021 Sep 16]. https://www.nytimes.com/2018/11/20/health/chicken-pox-vaccine-asheville.html.

  51. Oostvogel PM, van der Avoort HGAM, Mulders MN, van Loon AM, Conyn-van Spaendonck MAE, Rümke HC, et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992–93. Lancet. 1994;344(8923):665–70.

    Article  CAS  PubMed  Google Scholar 

  52. National Center for Immuization and Respiratory Diseases. Vaccines for Children Program (VFC). Centers for Disease Control and Prevention. Published February 18, 2016. https://www.cdc.gov/vaccines/programs/vfc. Accessed 28 Mar 2022.

  53. Chevalier-Cottin E-P, Ashbaugh H, Brooke N, Gavazzi G, Santillana M, Burlet N, et al. Communicating benefits from vaccines beyond preventing infectious diseases. Infect Dis Ther. 2020;9(3):467–80.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Cohn A, Rodewald LE, Orenstein WA, Schuchat A. Immunization in the United States. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Elsevier; 2018. p. 1421–1440.e4. https://doi.org/10.1016/B978-0-323-35761-6.00073-0.

    Chapter  Google Scholar 

  55. U.S. Food and Drug Administration. https://www.fda.gov/. Accessed 3 May 2022.

  56. Gruber MF, Marshall VB. Regulation and testing of vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Elsevier; 2018. p. 1547–1565.e2. https://doi.org/10.1016/B978-0-323-35761-6.00079-1.

    Chapter  Google Scholar 

  57. Advisory Committee on Immunization Practices. https://www.cdc.gov/vaccines/acip/index.html. Accessed 3 May 2022.

  58. Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111–148, 124 Stat. 119 (2010).

    Google Scholar 

  59. Johansen K, Pfeifer D, Salisbury D. Immunization in Europe. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Elsevier; 2018. p. 1441–1465.e7. https://doi.org/10.1016/B978-0-323-35761-6.00074-2.

    Chapter  Google Scholar 

  60. Standing Committee on Vaccination. https://www.rki.de/EN/Content/infections/Vaccination/Vaccination_node.html. Accessed 3 May 2022.

  61. Joint Committee on Vaccines and Immunisation. https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation. Accessed 3 May 2022.

  62. England PH. The Green Book [Internet]. 2020. https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book#the-green-book.

    Google Scholar 

  63. Cherian T, Cutts F, Eggers R, Lydon P, Sodha SV, Okwo-Bele JM. Immunization in developing countries. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KA, editors. Plotkin’s vaccines. 7th ed. Elsevier; 2018. p. 1486–1511.e5. https://doi.org/10.1016/B978-0-323-35761-6.00076-6.

    Chapter  Google Scholar 

  64. World Health Organization. Immunization Agenda 2030: a global strategy to leave no one behind. https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/ia2030. Accessed 3 May 2022.

  65. World Health Organization (WHO). WHO recommendations for routine immunization [Internet]. 2020. https://www.who.int/publications/m/item/table-1-who-recommendations-for-routine-immunization.

  66. World Health Organization (WHO). WHO vaccine-preventable diseases: monitoring system. 2020 global summary [Internet]. 2020. https://apps.who.int/immunization_monitoring/globalsummary/schedules.

  67. GAVI_Alliance. GAVI Progress Report [Internet]. 2020. https://www.gavi.org/sites/default/files/programmes-impact/our-impact/apr/Gavi-Progress-Report-2020.pdf.

  68. World Health Organization (WHO). Immunizations [Internet]. 2019. https://www.who.int/news-room/facts-in-pictures/detail/immunization.

  69. Ljungman P. Vaccination of immunocompromised hosts. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Elsevier; 2013:1243–1256. doi:https://doi.org/10.1016/B978-1-4557-0090-5.00016-1.

  70. Moore DL. Immunization of the immunocompromised child: key principles. Paediatr Child Health. 2018;23(3):203–5. https://doi.org/10.1093/pch/pxx180.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52.

    Article  CAS  PubMed  Google Scholar 

  72. Esposito S, Bruno C, Berardinelli A, et al. Vaccination recommendations for patients with neuromuscular disease. Vaccine. 2014;32(45):5893–900.

    Article  PubMed  Google Scholar 

  73. Pileggi GS, de Souza CBS, Ferriani VPL. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res. 2010;62(7):1034–9.

    Article  CAS  Google Scholar 

  74. Seitel T, Cagol L, Prelog M, et al. Varicella-zoster-virus vaccination of immunosuppressed children with inflammatory bowel disease or autoimmune hepatitis: a prospective observational study. Vaccine. 2020;38(50):8024–31.

    Article  CAS  PubMed  Google Scholar 

  75. Tse HN, Borrow R, Arkwright PD. Immune response and safety of viral vaccines in children with autoimmune diseases on immune modulatory drug therapy. Expert Rev Vaccines. 2020;19(12):1115–27.

    Article  CAS  PubMed  Google Scholar 

  76. Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Talbot HK, Poehling KA, Pilishvili T. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62(25):521–4. PMID: 23803961; PMCID: PMC4604951

    Google Scholar 

  78. Centers for Disease Control and Prevention (CDC). Pneumococcal vaccination: summary of who and when to vaccinate. Published January 24, 2022. https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html. Accessed 10 May 2022.

  79. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;22:2087–96.

    Article  Google Scholar 

  80. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Díez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32.

    Article  CAS  PubMed  Google Scholar 

  81. Racine É, Gilca V, Amini R, Tunis M, Ismail S, Sauvageau C. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18–49 year old patients. Vaccine. 2020;38(40):6205–14.

    Article  PubMed  Google Scholar 

  82. Centers for Disease Control and Prevention (CDC). Shingrix recommendations. CDC. Published January 24, 2022. https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/recommendations.html#:~:text=CDC%20recommends%20Shingrix%20(recombinant%20zoster,prior%20episode%20of%20herpes%20zoster. Accessed 9 May 2022.

  83. Centers for Disease Control and Prevention (CDC). Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. CDC. Published February 15, 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed 11 May 2022.

  84. Righi E, Gallo T, Azzini AM, et al. A review of vaccinations in adult patients with secondary immunodeficiency. Infect Dis Ther. 2021;10(2):637–61.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Kruk SK, Pacheco SE, Koenig MK, Bergerson JRE, Gordon-Lipkin E, McGuire PJ. Vulnerability of pediatric patients with mitochondrial disease to vaccine-preventable diseases. J Allerg Clin Immunol Pract. 2019;7(7):2415–2418.e3.

    Article  Google Scholar 

  86. Centers for Disease Control and Prevention (CDC). Vaccines indicated for adults based on medical indications. CDC. Published February 12, 2021. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions-shell.html. Accessed 16 Sept 2021.

  87. Centers for Disease Control and Prevention (CDC). Vaccines indicated for persons aged 0 through 18 years based on medical indications. CDC. Published February 12, 2021. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-indications.html. Accessed 16 Sept 2021.

  88. Zeitlin PL, Leong M, Cole J, et al. Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial. J Asthma Allergy. 2018;11:181–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Tang YW, Graham BS. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Investig. 1994;94(5):1953–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Cuellar-Barboza A, Zirwas M, Feldman SR. Is dupilumab an immunosuppressant? J Drugs Dermatol. 2020;19(2).

    Google Scholar 

  91. Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair®), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol. 2005;29(1):31–48.

    Article  CAS  PubMed  Google Scholar 

  92. Mepolizumab. LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases. Published online April 11, 2016. https://www.ncbi.nlm.nih.gov/books/NBK548052/. Accessed 16 Sept 2021.

  93. Reslizumab. LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases. Published online March 14, 2017. https://www.ncbi.nlm.nih.gov/books/NBK548383/. Accessed 16 Sept 2021.

  94. Mirsaeidi M, Ebrahimi G, Allen MB, Aliberti S. Pneumococcal vaccine and patients with pulmonary diseases. Am J Med. 2014;127(9):886.e1–8.

    Article  CAS  PubMed  Google Scholar 

  95. Tan B, Ismail S. Updated recommendations for the use of varicella and MMR vaccines in HIV-infected individuals. Can Commun Dis Rep. 2010;36(ACS-7):1–19.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Vaccination of HIV infected children (UK Schedule, 2018). Children’s HIV Association. Published 2018. https://www.chiva.org.uk/infoprofessionals/guidelines/immunisation/. Accessed 16 Sept 2021.

  97. World Health Organization. BCG vaccines: WHO position paper -- February 2018. Wkly Epidemiol Rec. 2018;93(8):73–96. https://apps.who.int/iris/handle/10665/260307. Accessed 8 Sept 2021

    Google Scholar 

  98. Lee GM. Preventing infections in children and adults with asplenia. Hematol Am Soc Hematol Educ Program. 2020;1:328–35.

    Article  Google Scholar 

  99. Briere EC, Rubin L, Moro PL, et al. Prevention and control of Haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-01):1–14.

    PubMed  Google Scholar 

  100. Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, MacNeil JR. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1–41.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Centers for Disease Control and Prevention (CDC). Varicella vaccine recommendations. CDC. Published April 28, 2021. https://www.cdc.gov/vaccines/vpd/varicella/hcp/recommendations.html. Accessed 9 May 2022.

  102. National Center for Immunization and Respiratory Diseases. Clinical considerations for use of recombinant zoster vaccine (RZV, Shingrix) in immunocompromised adults aged >/=19 Years. Centers for Disease Control and Prevention (CDC). Published January 20, 2022. https://www.cdc.gov/shingles/vaccination/immunocompromised-adults.html. Accessed 9 May 2022.

  103. Pittet LF, Posfay-Barbe KM. Vaccination of immune compromised children—an overview for physicians. Eur J Pediatr. 2021;180(7):2035–47.

    Article  PubMed  PubMed Central  Google Scholar 

  104. MacDonald SE, Palichuk A, Slater L, Tripp H, Reifferscheid L, Burton C. Gaps in knowledge about the vaccine coverage of immunocompromised children: a scoping review. Hum Vaccin Immunother. 2021;16:1–16.

    Google Scholar 

  105. Hofstetter AM, Camargo S, Natarajan K, Rosenthal SL, Stockwell MS. Vaccination coverage of adolescents with chronic medical conditions. Am J Prev Med. 2017;53(5):680–8.

    Article  PubMed  Google Scholar 

  106. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev. 2020;16(5):442–9.

    PubMed  PubMed Central  Google Scholar 

  107. Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007;23(1):3–13.

    Article  CAS  PubMed  Google Scholar 

  108. Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol. 2020;11:1582.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Grohskopf LA, Alyanak E, Broder KR, Blanton LH, Fry AM, Jernigan DB, Atmar RL. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2020–21 influenza season. MMWR Recomm Rep. 2020;69(8):1–24.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Dos Santos G, Tahrat H, Bekkat-Berkani R. Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: a systematic review. Hum Vaccin Immunother. 2018;14(8):1853–66.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Weng MK, Doshani M, Khan MA, Frey S, Ault K, Moore KL, Hall EW, Morgan RL, Campos-Outcalt D, Wester C, Nelson NP. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477–83.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Centers for Diseases Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60(50):1709–11.

    Google Scholar 

  113. Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: current concepts, uncertainties and challenges. Diabetes Metab Syndr. 2021;15(2):505–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. USRDS Annual Report: morbidity and mortality in patients with CKD [Internet]. [cited 2021 Jun 14]. https://adr.usrds.org/2020/chronic-kidney-disease/3-mobidity-and-mortality-in-patients-with-ckd.

  115. Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin Exp Nephrol. 2019;23(4):437–47.

    Article  PubMed  Google Scholar 

  116. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5):1526–33.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Renal Nutr. 2012;22(1):149–56.

    Article  CAS  Google Scholar 

  118. Su G, Iwagami M, Qin X, McDonald H, Liu X, Carrero JJ, et al. Kidney disease and mortality in patients with respiratory tract infections: a systematic review and meta-analysis. Clin Kidney J. 2021;14(2):602–11.

    Article  CAS  PubMed  Google Scholar 

  119. Gilbertson DT, Rothman KJ, Chertow GM, Bradbury BD, Brookhart MA, Liu J, et al. Excess deaths attributable to influenza-like illness in the ESRD population. J Am Soc Nephrol. 2019;30(2):346–53.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet (London, England). 2015;386(10003):1546–55.

    Article  PubMed  Google Scholar 

  122. Fabrizi F, Marzano A, Messa P, Martin P, Lampertico P. Hepatitis B virus infection in the dialysis population: current perspectives. Int J Artif Organs. 2008;31(5):386–94.

    Article  CAS  PubMed  Google Scholar 

  123. Advisory Committee on Immunization Practices. Recommended adult immunization schedule by medical condition and other indications, United States, 2021 [Internet]. [cited 2021 Jun 14]. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html#notes.

  124. Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule for ages 19 years or older: United States, 2021 [Internet]. Vol. 34. 2021 [cited 2021 Jun 15]. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html#table-age.

  125. Centers for Disease Control and Prevention (CDC). Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2021 [Internet]. [cited 2021 Jun 15]. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html#birth-15.

  126. Watcharananan SP, Thakkinstian A, Srichunrasmee C, Chuntratita W, Sumethkul V. Comparison of the immunogenicity of a monovalent influenza A/H1N1 2009 vaccine between healthy individuals, patients with chronic renal failure, and immunocompromised populations. Transplant Proc. 2014;46(2):328–31.

    Article  CAS  PubMed  Google Scholar 

  127. Broeders NE, Hombrouck A, Lemy A, Wissing KM, Racapé J, Gastaldello K, et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol. 2011;6(11):2573–8.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Ishigami J, Sang Y, Grams ME, Coresh J, Chang A, Matsushita K. Effectiveness of influenza vaccination among older adults across kidney function: pooled analysis of 2005–2006 through 2014–2015 influenza seasons. Am J Kidney Dis. 2020;75(6):887–96.

    Article  PubMed  Google Scholar 

  129. Noh JY, Song JY, Choi WS, Lee J, Bin SY, Kwon YJ, et al. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines. Hum Vaccin Immunother. 2016;12(11):2902–8.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Lee JKH, Lam GKL, Shin T, Kim J, Krishnan A, Greenberg DP, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. 2018;17(5):435–43.

    Article  CAS  PubMed  Google Scholar 

  131. Butler AM, Layton JB, Dharnidharka VR, Sahrmann JM, Seamans MJ, Weber DJ, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccine among patients receiving maintenance hemodialysis. Am J Kidney Dis. 2020;75(1):72–83.

    Article  PubMed  Google Scholar 

  132. Weycker D, Farkouh RA, Strutton DR, Edelsberg J, Shea KM, Pelton SI. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res. 2016;16:182.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28(31):4955–60.

    Article  PubMed  Google Scholar 

  134. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;(1):CD000422.

    Google Scholar 

  135. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180(1):48–58.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Mahmoodi M, Aghamohammadi A, Rezaei N, Lessan-Pezeshki M, Pourmand G, Mohagheghi M-A, et al. Antibody response to pneumococcal capsular polysaccharide vaccination in patients with chronic kidney disease. Eur Cytokine Netw. 2009;20(2):69–74.

    Article  CAS  PubMed  Google Scholar 

  137. Vandecasteele SJ, De Bacquer D, Caluwe R, Ombelet S, Van Vlem B. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study. Clin Microbiol Infect. 2018;24(1):65–71.

    Article  CAS  PubMed  Google Scholar 

  138. Centers for Disease Control and Prevention (CDC). Preventing pneumococcal disease among infants and young children [Internet]. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4909a1.htm.

  139. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010;362(9):812–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine. 2001;20(3–4):545–53.

    Article  CAS  PubMed  Google Scholar 

  141. Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1–18.

    PubMed  Google Scholar 

  142. Ghadiani MH, Besharati S, Mousavinasab N, Jalalzadeh M. Response rates to HB vaccine in CKD stages 3–4 and hemodialysis patients. J Res Med Sci. 2012;17(6):527–33.

    PubMed  PubMed Central  Google Scholar 

  143. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42(6):1184–92.

    Article  PubMed  Google Scholar 

  144. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999;33(2):356–60.

    Article  CAS  PubMed  Google Scholar 

  145. Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67(15):455–8.

    Article  PubMed  PubMed Central  Google Scholar 

  146. Centers for Disease Control and Prevention (CDC). Guidelines for vaccination renal dialysis patients and patients with chronic kidney disease. [Internet]. [cited 2021 Jun 14]. https://www.cdc.gov/dialysis/PDFs/Vaccinating_Dialysis_Patients_and_Patients_dec2012.pdf.

  147. Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis. 2017;12:3457–68. https://doi.org/10.2147/COPD.S140378.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Hewitt R, Farne H, Ritchie A, Luke E, Johnston SL, Mallia P. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. 2016;10(2):158–74.

    Article  PubMed  Google Scholar 

  149. BurgessL SK. Cochrane Library Cochrane Database of Systematic Reviews Pneumococcal vaccines for cystic fibrosis (Review). 2016.; www.cochranelibrary.com.

    Google Scholar 

  150. Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1(1):CD001390.

    PubMed  Google Scholar 

  151. Sheen YH, Kizilbash S, Ryoo E, Wi C-I, Park M, Abraham RS, et al. Relationship between asthma status and antibody response pattern to 23-valent pneumococcal vaccination. J Asthma. 2020; Apr 2 [cited 2021 Oct 13];57(4):1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702096/

  152. Cochrane Library Cochrane Database of Systematic Reviews. Influenza vaccine for chronic obstructive pulmonary disease (COPD) (Review) Influenza vaccine for chronic obstructive pulmonary disease (COPD) (Review). 2018. www.cochranelibrary.com.

  153. Vasileiou E, Sheikh A, Butler C, El Ferkh K, von Wissmann B, McMenamin J, Ritchie L, Schwarze J, Papadopoulos NG, Johnston SL, Tian L, Simpson CR. Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis. Clin Infect Dis. 2017;65(8):1388–95.

    Article  PubMed  PubMed Central  Google Scholar 

  154. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001;33(1):41–8.

    Article  CAS  PubMed  Google Scholar 

  155. Piano S, Tonon M, Angeli P. Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin Mol Hepatol. 2021;27(3):437–45.

    Article  PubMed  PubMed Central  Google Scholar 

  156. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319–34.

    Article  PubMed  PubMed Central  Google Scholar 

  157. Su F-H, Huang Y-L, Sung F-C, Su C-T, Hsu W-H, Chang S-N, et al. Annual influenza vaccination reduces total hospitalization in patients with chronic hepatitis B virus infection: a population-based analysis. Vaccine. 2016;34(1):120–7.

    Article  PubMed  Google Scholar 

  158. Gaeta GB, Stornaiuolo G, Precone DF, Amendola A, Zanetti AR. Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine. 2002;20(Suppl 5):B33–5.

    Article  PubMed  Google Scholar 

  159. Gaeta GB, Pariani E, Amendola A, Brancaccio G, Cuomo G, Stornaiuolo G, et al. Influenza vaccination in patients with cirrhosis and in liver transplant recipients. Vaccine. 2009;27(25–26):3373–5.

    Article  CAS  PubMed  Google Scholar 

  160. Härmälä S, Parisinos CA, Shallcross L, O’Brien A, Hayward A. Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis. BMJ Open. 2019;9(9):e031070.

    Article  PubMed  PubMed Central  Google Scholar 

  161. Baxter R, Yee A, Aukes L, Snow V, Fireman B, Atkinson B, et al. Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016;34(36):4293–7.

    Article  PubMed  Google Scholar 

  162. Gransden WR, Eykyn SJ, Phillips I. Pneumococcal bacteraemia: 325 episodes diagnosed at St Thomas’s Hospital. Br Med J (Clin Res Ed). 1985;290(6467):505–8.

    Article  CAS  PubMed  Google Scholar 

  163. McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis. 2000;181(2):757–60.

    Article  CAS  PubMed  Google Scholar 

  164. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338(5):286–90.

    Article  CAS  PubMed  Google Scholar 

  165. Younossi ZM, Stepanova M. Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. Hepatology (Baltimore, Md). 2011;54(4):1167–78.

    Article  PubMed  Google Scholar 

  166. Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology (Baltimore, Md). 2001;34(1):28–31.

    Article  CAS  PubMed  Google Scholar 

  167. Leise MD, Talwalkar JA. Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep. 2013;15(1):300.

    Article  PubMed  Google Scholar 

  168. Horlander JC, Boyle N, Manam R, Schenk M, Herring S, Kwo PY, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci. 1999;318(5):304–7.

    Article  CAS  PubMed  Google Scholar 

  169. Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance. Clin Liver Dis. 2018;12(1):33–4.

    Article  Google Scholar 

  170. Omer SB. Maternal immunization. N Engl J Med. 2017;376(13):1256–67.

    Article  CAS  PubMed  Google Scholar 

  171. Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol. 2011;205(1):10–8.

    Article  PubMed  Google Scholar 

  172. Martin A, Cox S, Jamieson DJ, Whiteman MK, Kulkarni A, Tepper NK. Respiratory illness hospitalizations among pregnant women during influenza season, 1998–2008. Matern Child Health J. 2013;17(7):1325–31.

    Article  PubMed  PubMed Central  Google Scholar 

  173. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med. 2008;359(15):1555–64.

    Article  CAS  PubMed  Google Scholar 

  174. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women—Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013;62(7):131–5. PMID: 23425962; PMCID: PMC4604886

    Google Scholar 

  175. Munoz FM, Jamieson DJ. Maternal immunization. Obstet Gynecol. 2019;133(4):739–53.

    Article  PubMed  Google Scholar 

  176. Alonso S, Vidal M, Ruiz-Olalla G, González R, Manaca MN, Jairoce C, et al. Reduced placental transfer of antibodies against a wide range of microbial and vaccine antigens in HIV-infected women in Mozambique. Front Immunol. 2021;12:614246.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  177. Cavalcante RS, Kopelman BI, Costa-Carvalho BT. Placental transfer of Haemophilus influenzae type b antibodies in malnourished pregnant women. Braz J Infect Dis. 2008;12(1):47–51.

    Article  CAS  PubMed  Google Scholar 

  178. de Souza EG, Hara CCP, Fagundes DLG, de Queiroz AA, Morceli G, Calderon IMP, et al. Maternal-foetal diabetes modifies neonatal Fc receptor expression on human leucocytes. Scand J Immunol. 2016;84(4):237–44.

    Article  PubMed  Google Scholar 

  179. Wilcox CR, Holder B, Jones CE. Factors affecting the FcRn-mediated transplacental transfer of antibodies and implications for vaccination in pregnancy. Front Immunol. 2017;8:1294.

    Article  PubMed  PubMed Central  Google Scholar 

  180. Chung S, Baumlin N, Dennis JS, Moore R, Salathe SF, Whitney PL, et al. Electronic cigarette vapor with nicotine causes airway mucociliary dysfunction preferentially via TRPA1 receptors. Am J Respir Crit Care Med. 2019;200(9):1134–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  181. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004;164(20):2206–16.

    Article  PubMed  Google Scholar 

  182. Xavier RF, Ramos D, Ito JT, Rodrigues FMM, Bertolini GN, Macchione M, et al. Effects of cigarette smoking intensity on the mucociliary clearance of active smokers. Respiration. 2013;86(6):479–85.

    Article  CAS  PubMed  Google Scholar 

  183. Shastri MD, Shukla SD, Chong WC, Rajendra KC, Dua K, Patel RP, et al. Smoking and COVID-19: what we know so far. Respir Med. 2021;176:106237.

    Article  PubMed  Google Scholar 

  184. Lawrence H, Hunter A, Murray R, Lim WS, McKeever T. Cigarette smoking and the occurrence of influenza – systematic review. J Infect. 2019;79(5):401–6.

    Article  CAS  PubMed  Google Scholar 

  185. Raman AS, Swinburne AJ, Fedullo AJ. Pneumococcal adherence to the buccal epithelial cells of cigarette smokers. Chest. 1983;83(1):23–7.

    Article  CAS  PubMed  Google Scholar 

  186. Bello S, Menéndez R, Antoni T, Reyes S, Zalacain R, Capelastegui A, et al. Tobacco smoking increases the risk for death from pneumococcal pneumonia. Chest. 2014;146(4):1029–37.

    Article  PubMed  Google Scholar 

  187. Baskaran V, Murray RL, Hunter A, Lim WS, McKeever TM. Effect of tobacco smoking on the risk of developing community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2019;14(7):e0220204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Lowe KE, Zein J, Hatipoglu U, Attaway A. Association of smoking and cumulative pack-year exposure with COVID-19 outcomes in the Cleveland Clinic COVID-19 Registry. JAMA Intern Med. 2021;181(5):709–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  189. Espejo-Paeres C, Núñez-Gil IJ, Estrada V, Fernández-Pérez C, Uribe-Heredia G, Cabré-Verdiell C, et al. Impact of smoking on COVID-19 outcomes: a HOPE Registry subanalysis. BMJ Nutr Prev Health. 2021;4(1):285–92.

    Article  PubMed  PubMed Central  Google Scholar 

  190. Mahabee-Gittens EM, Mendy A, Merianos AL. Assessment of severe COVID-19 outcomes using measures of smoking status and smoking intensity. Int J Environ Res Public Health. 2021;18(17):8939.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  191. Han L, Ran J, Mak Y-W, Suen LK-P, Lee PH, Peiris JSM, et al. Smoking and influenza-associated morbidity and mortality. Epidemiology. 2019;30(3):405–17.

    Article  PubMed  Google Scholar 

  192. Godoy P, Castilla J, Mayoral JM, Delgado-Rodríguez M, Martín V, Astray J, et al. Smoking may increase the risk of hospitalization due to influenza. Eur J Public Health. 2016;26(5):882–7.

    Article  PubMed  Google Scholar 

  193. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057–65.

    Article  PubMed  Google Scholar 

  194. Dooling K, Marin M, Wallace M, McClung N, Chamberland M, Lee GM, et al. The Advisory Committee on Immunization Practices’ updated interim recommendation for allocation of COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1657–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  195. Centers for Disease Control and Prevention (CDC). Frequently asked questions: questions about flu season and the use of E-cigarette, or vaping, products [Internet]. CDC Office on Smoking and Tobacco Use. 2020 [cited 2021 Sep 16]. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease/faq/index.html.

  196. Solórzano-Santos F, Espinoza-García L, Aguilar-Martínez G, Beirana-Palencia L, Echániz-Avilés G, Miranda-Novales G. Pneumococcal conjugate vaccine and pneumonia prevention in children with congenital heart disease. Rev Investig Clin. 2017;69(5):270–3.

    Google Scholar 

  197. Ghimire LV, Chou F-S, Moon-Grady AJ. Impact of congenital heart disease on outcomes among pediatric patients hospitalized for influenza infection. BMC Pediatr. 2020;20(1):450.

    Article  PubMed  PubMed Central  Google Scholar 

  198. Walmsley D. Routine pediatric immunization, special cases in pediatrics: prematurity, chronic disease, congenital heart disease: recent advancements/changes in pediatric vaccines. Prim Care. 2011;38(4):595–609.

    Article  PubMed  Google Scholar 

  199. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2).

    Google Scholar 

  200. Respiratory syncytial virus prophylaxis for high-risk infants program reference manual [Internet]. Ottawa; 2021 Oct [cited 2021 Oct 14]. https://www.health.gov.on.ca/en/pro/programs/drugs/funded_drug/fund_respiratory.aspx.

  201. Ramsay M. Respiratory syncytial virus. In: Ramsay M, editor. Immunisation against infectious disease: the Green Book. London: Public Health England; 2020.

    Google Scholar 

  202. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA. 1985;254(22):3187–9.

    Article  CAS  PubMed  Google Scholar 

  203. Van der Wielen M, Van Damme P, Chlibek R, Smetana J, von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine. 2006;24(26):5509–15.

    Article  PubMed  Google Scholar 

  204. Eliakim A, Schwindt C, Zaldivar F, Casali P, Cooper DM. Reduced tetanus antibody titers in overweight children. Autoimmunity. 2006;39(2):137–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  205. Louie JK, Acosta M, Samuel MC, Schechter R, Vugia DJ, Harriman K, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis. 2011;52(3):301–12.

    Article  PubMed  Google Scholar 

  206. Callahan ST, Wolff M, Hill HR, Edwards KM. Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults. J Infect Dis. 2014;210(8):1270–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  207. Talbot HK, Coleman LA, Crimin K, Zhu Y, Rock MT, Meece J, et al. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine. 2012;30(26):3937–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  208. Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes (2005). 2012;36(8):1072–7.

    Article  CAS  Google Scholar 

  209. U.S. Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine. Accessed 3 May 2022.

  210. U.S. Food and Drug Administration. Spikevax and Moderna COVID-19 vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine#:~:text=On%20January%2031%2C%202022%2C%20the,years%20of%20age%20and%20older. Accessed 3 May 2022.

  211. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.

    Article  CAS  PubMed  Google Scholar 

  212. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.

    Article  CAS  PubMed  Google Scholar 

  213. Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al. Clinical characterization and prediction of clinical severity of SARS-CoV-2 infection among US adults using data from the US National COVID Cohort Collaborative. JAMA Netw Open. 2021;4(7):e2116901.

    Article  PubMed  PubMed Central  Google Scholar 

  214. Kondrich J, Rosenthal M. Influenza in children. Curr Opin Pediatr. 2017;29(3):297–302.

    Article  PubMed  Google Scholar 

  215. Keren R. Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. JAMA. 2005;294(17):2188–94.

    Article  CAS  PubMed  Google Scholar 

  216. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024.

    Article  PubMed  PubMed Central  Google Scholar 

  217. Pneumococcal vaccine: Canadian Immunization Guide - Canada.ca [Internet]. Government of Canada. 2016 [cited 2021 Sep 16]. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html.

  218. Pneumococcal vaccine [Internet]. Health Service Executive of Ireland National Immunisation Office. 2019 [cited 2021 Sep 16]. https://www.hse.ie/eng/health/immunisation/hcpinfo/othervaccines/pneumo/#Who%20is%20most%20at%20risk%20of%20pneumococcal%20disease?

  219. Complete routine immunisation schedule [Internet]. Public Health England. 2020 [cited 2021 Sep 16]. https://www.gov.uk/government/publications/the-complete-routine-immunisation-schedule.

  220. Ramsay M. Pneumococcal. In: Ramsay M, editor. Immunisation against infectious disease: the Green Book. London: Public Health England; 2020.

    Google Scholar 

  221. Kasarskis E. FYI: Influenza and ALS [Internet]. The ALS Association. 2020 [cited 2021 Sep 16]. https://www.als.org/navigating-als/resources/fyi-influenza-and-als.

  222. Alkon C. Are vaccines safe? | Muscular Dystrophy Association. Quest Magazine of the Muscular Dystrophy Association [Internet]. 2021 Mar 4 [cited 2021 Sep 16]. https://www.mda.org/quest/article/are-vaccines-safe.

  223. Gierke R, Wodi P, Kobayashi M. Pneumococcal disease. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, editors. The Pinkbook: epidemiology and prevention of vaccine-preventable diseases. 14th ed. Washington, DC: Centers for Disease Control and Prevention; 2021.

    Google Scholar 

  224. Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2021;96(3):114–22.

    Article  PubMed  PubMed Central  Google Scholar 

  225. Centers for Disease Control and Prevention (CDC). Vaccines indicated for adults based on medical indications [Internet]. CDC. 2021 [cited 2021 Sep 16]. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions-shell.html.

  226. Kaufman J, Tuckerman J, Bonner C, Durrheim DN, Costa D, Trevena L, Thomas S, Danchin M. Parent-level barriers to uptake of childhood vaccination: a global overview of systematic reviews. BMJ Glob Health. 2021;6(9):e006860. https://doi.org/10.1136/bmjgh-2021-006860.

    Article  PubMed  PubMed Central  Google Scholar 

  227. Jarrett C, Wilson R, O’Leary M, Eckersberger E, Larson HJ, SAGE Working Group on Vaccine Hesitancy. Strategies for addressing vaccine hesitancy - a systematic review. Vaccine. 2015;33(34):4180–90.

    Article  PubMed  Google Scholar 

  228. Singh P, Dhalaria P, Kashyap S, Soni GK, Nandi P, Ghosh S, Mohapatra MK, Rastogi A, Prakash D. Strategies to overcome vaccine hesitancy: a systematic review. Syst Rev. 2022;11(1):78.

    Article  PubMed  PubMed Central  Google Scholar 

  229. Szilagyi P, Vann J, Bordley C, Chelminski A, Kraus R, Margolis P, Rodewald L. Interventions aimed at improving immunization rates. Cochrane Database Syst Rev. 2002;(4):CD003941. https://doi.org/10.1002/14651858.CD003941. Update in: Cochrane Database Syst Rev. 2005;(3):CD003941.

  230. Groom H, Hopkins DP, Pabst LJ, Murphy Morgan J, Patel M, Calonge N, Coyle R, Dombkowski K, Groom AV, Kurilo MB, Rasulnia B, Shefer A, Town C, Wortley PM, Zucker J, Community Preventive Services Task Force. Immunization information systems to increase vaccination rates: a community guide systematic review. J Public Health Manag Pract. 2015;21(3):227–48.

    Article  PubMed  Google Scholar 

  231. Centers for Disease Control and Prevention (CDC). The community guide, vaccination [Internet]. 2015. https://www.thecommunityguide.org/topic/vaccination?page=1.

  232. Brewer NT, Hall ME, Malo TL, Gilkey MB, Quinn B, Lathren C. Announcements versus conversations to improve HPV vaccination coverage: a randomized trial. Pediatrics. 2017;139(1):e20161764.

    Article  PubMed  PubMed Central  Google Scholar 

  233. Opel DJ, Zhou C, Robinson JD, Henrikson N, Lepere K, Mangione-Smith R, et al. Impact of childhood vaccine discussion format over time on immunization status. Acad Pediatr. 2018;18(4):430–6.

    Article  PubMed  PubMed Central  Google Scholar 

  234. Dempsey AF, Pyrznawoski J, Lockhart S, Barnard J, Campagna EJ, Garrett K, et al. Effect of a health care professional communication training intervention on adolescent human papillomavirus vaccination: a cluster randomized clinical trial. JAMA Pediatr. 2018;172(5):e180016.

    Article  PubMed  PubMed Central  Google Scholar 

  235. Jarrett C, Wilson R, O’Leary M, Eckersberger E, Larson HJ. Strategies for addressing vaccine hesitancy - a systematic review. Vaccine. 2015;33(34):4180–90.

    Article  PubMed  Google Scholar 

  236. Dubé E, Gagnon D, MacDonald NE. Strategies intended to address vaccine hesitancy: review of published reviews. Vaccine. 2015;33(34):4191–203.

    Article  PubMed  Google Scholar 

  237. Vielot NA, Islam JY, Sanusi B, Myers J, Smith S, Meadows B, et al. Overcoming barriers to adolescent vaccination: perspectives from vaccine providers in North Carolina. Women Health. 2020;60(10):1129–40.

    Article  PubMed  PubMed Central  Google Scholar 

  238. Sabnis SS, Pomeranz AJ, Amateau MM. The effect of education, feedback, and provider prompts on the rate of missed vaccine opportunities in a community health center. Clin Pediatr. 2003;42(2):147–51.

    Article  Google Scholar 

  239. McAdam-Marx C, Tak C, Petigara T, Jones NW, Yoo M, Briley MS, et al. Impact of a guideline-based best practice alert on pneumococcal vaccination rates in adults in a primary care setting. BMC Health Serv Res. 2019;19(1):474.

    Article  PubMed  PubMed Central  Google Scholar 

  240. Klatt TE, Hopp E. Effect of a best-practice alert on the rate of influenza vaccination of pregnant women. Obstet Gynecol. 2012;119(2 Pt 1):301–5.

    Article  PubMed  Google Scholar 

  241. Ledwich LJ, Harrington TM, Ayoub WT, Sartorius JA, Newman ED. Improved influenza and pneumococcal vaccination in rheumatology patients taking immunosuppressants using an electronic health record best practice alert. Arthritis Rheum. 2009;61(11):1505–10.

    Article  PubMed  Google Scholar 

  242. Bardenheier BH, Shefer AM, Lu P-J, Remsburg RE, Marsteller JA. Are standing order programs associated with influenza vaccination? - NNHS, 2004. J Am Med Dir Assoc. 2010;11(9):654–61.

    Article  PubMed  Google Scholar 

  243. Coyle CM, Currie BP. Improving the rates of inpatient pneumococcal vaccination: impact of standing orders versus computerized reminders to physicians. Infect Control Hosp Epidemiol. 2004;25(11):904–7.

    Article  PubMed  Google Scholar 

  244. Dexter PR, Perkins SM, Maharry KS, Jones K, McDonald CJ. Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates: a randomized trial. JAMA. 2004;292(19):2366–71.

    Article  CAS  PubMed  Google Scholar 

  245. Daley MF, Barrow J, Pearson K, Crane LA, Gao D, Stevenson JM, et al. Identification and recall of children with chronic medical conditions for influenza vaccination. Pediatrics. 2004;113(1 Pt 1):e26–33.

    Article  PubMed  Google Scholar 

  246. Suh CA, Saville A, Daley MF, Glazner JE, Barrow J, Stokley S, et al. Effectiveness and net cost of reminder/recall for adolescent immunizations. Pediatrics. 2012;129(6):e1437–45.

    Article  PubMed  Google Scholar 

  247. Dini EF, Linkins RW, Sigafoos J. The impact of computer-generated messages on childhood immunization coverage. Am J Prev Med. 2000;18(2):132–9.

    Article  CAS  PubMed  Google Scholar 

  248. Bordley WC, Chelminski A, Margolis PA, Kraus R, Szilagyi PG, Vann JJ. The effect of audit and feedback on immunization delivery: a systematic review. Am J Prev Med. 2000;18(4):343–50.

    Article  CAS  PubMed  Google Scholar 

  249. Brousseau N, Sauvageau C, Ouakki M, Audet D, Kiely M, Couture C, et al. Feasibility and impact of providing feedback to vaccinating medical clinics: evaluating a public health intervention. BMC Public Health. 2010;10:750.

    Article  PubMed  PubMed Central  Google Scholar 

  250. Kiefe CI, Allison JJ, Williams OD, Person SD, Weaver MT, Weissman NW. Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. JAMA. 2001;285(22):2871–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Teaching Program, Cone Health, Greensboro, NC, USA

    Zachary J. Pettigrew

  2. Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Min Kim

  3. Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Sylvia Becker-Dreps

Authors
  1. Zachary J. Pettigrew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sylvia Becker-Dreps
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sylvia Becker-Dreps .

Editor information

Editors and Affiliations

  1. Department of Family Medicine, University of North Carolina, CHAPEL HILL, NC, USA

    Timothy P. Daaleman

  2. Department of Family Medicine, University of North Carolina, CHAPEL HILL, NC, USA

    Margaret R. Helton

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pettigrew, Z.J., Kim, M., Becker-Dreps, S. (2023). Vaccines and Immunization. In: Daaleman, T.P., Helton, M.R. (eds) Chronic Illness Care. Springer, Cham. https://doi.org/10.1007/978-3-031-29171-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-29171-5_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-29170-8

  • Online ISBN: 978-3-031-29171-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation